Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2462 94 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2462Earnings in a few more weeks - hopefully big push from that.Felix B-last Friday
2461V Roy, ans second half of 2018 options are gone. It was pMiljenko Zuanic-last Thursday Off-label opportunity for Kevzara!Miljenko Zuanic-June 29
2459Chairman is special issue, still way OVERPAY! Also, am not sure what he did allMiljenko Zuanic-June 26
2458I can't believe how much they pay members of the board....Felix B-June 25
2457RE Dupi: NICE finial blessing, price at "£1,264.89 per pack of 2x2 ml Miljenko Zuanic-June 22
2456VPR, This is not a rush, but also it is not end-of-year confidence as well!? invMiljenko Zuanic-June 22
2455With start of the GBM trial, is REGN interested in vaccine or IL-12 pro-drug? imMiljenko Zuanic-June 22
2454Appears to be bouncing off a nice base. Long over 327 for a run up to 382. [grAlejandroo Green-June 20
2453Another story on canakinumab (Ilaris). Effect on lung cancer: theoncologist.alpMiljenko Zuanic-June 19 Infectious program initiatives from(for) REGN!Miljenko Zuanic-June 19
2451I never know what to make of technical analysis...Felix B-June 18
2450We may have here an upside runner to watch. Looking for breakout at 320.60 for aAlejandroo Green-June 18
2449To stop development of the Arcalyst (IL-1beta trap) ...was a good decision, as cMiljenko Zuanic-June 16
2448Remind me, they stopped developing arclyst for royalties?Felix B-June 16
2447RE: JAK1/2 for "at risk": Message 31659561Miljenko Zuanic-June 15
2446RE: anti-IL-1 Arcalyst was discontinued for gout, now Ilaris (NVS) Miljenko Zuanic-June 14
2445Well, combo is needed to achieve meaningful numbers of CRs as well as durable PRMiljenko Zuanic-June 13
2444Their commercialization efforts have been lackluster, perhaps the new chief of cFelix B-June 12
2443Based on pre-clinical REGN2810 data, it is. Will they be able to monetize it, itMiljenko Zuanic-June 12
2442So do you think there is any hope for REGN in the I/O field?Felix B-June 12
2441Keytruda approved for cervical cancer based on ORR, while REGN is doing overall Miljenko Zuanic-June 12
2440Not quite like buying shares on the open market, but I will take it! I continueBiotech Jim-June 12
2439First lot of Sanofi holding landed in REGN hand! secfilings.nasdaq.comMiljenko Zuanic-June 12
2438Yan at Byram Hills, and other ....With all this continuous presentation here andMiljenko Zuanic-June 8
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.